中国药理学会药物基因组学专业委员会

中国药理学会药物基因组学专业委员会简介：药物基因组学是研究个体基因的遗传学特征如何影响药物反应的科学，是药物学和遗传学的交叉学科，是人类进入功能基因组学研究后出现的一门新兴交叉学科。中国药理学会药物基因组学专业委员会己经中国药理学会九届常务理事会第八次会议审议同意成立，主发起人是中南大学临床药理研究所所长周宏灏院士。本专业委员会针对临床个体化药物治疗和合理用药这一核心进行理论、教育、技术、临床应用的研究和实践工作，按技术分工包括分析技术和临床应用两部分；从学术研究领域，主要是对基因多态-药代动力性-药效动力学三者关系及其各环节作用进行药物分析、分子生物学、细胞生物学、药理学、统计学等多学科的专业应用基础及标准化研究。

这一委员会的成立是我国药物基因组学和个体化医疗发展的一个重要里程碑，标志着我国药物基因组学和个体化医疗的研究和应用迈入一个新的发展阶段。这一委员会是我国药物基因组学和个体化医疗的领头羊，必将引领和带动我国药物基因组学、个体化医疗和转化医学的发展，同时也为我国在这些领域的科研人员、医务工作者和企业界人士，搭建了一个交流和合作的平台。以后本学会将定期或不定期举办各种学术活动，也欢迎大家在不同地区举办各种交流活动，争取未来将药物基因组学的学术大会发展为该领域每年一次或每两年一次的学术盛会。

中国药理学会药物基因组学专业委员会第一届委员会组成名单

主任委员： 周宏灏

副主任委员：贺林、陈超

秘书长： 张 伟

副秘书长： 崔一民、秦胜营、刘端

常委（排名不分先后）：程京、陈 忠、黄 民、李校堃、刘昭前、罗永章、马骏、沈洪兵、石乐明、唐北沙、汪道文、袁洪、张承绪、周智广、朱院山、林旭、魏伟、仝小林、秦莹、蔡卫民、陈恩强、陈枢青、陈翔、郭瑞臣、郭启勇、李一石、刘奇、刘泽源、苏乐群、叶启发、张玉、周云峰、顾东风、郭代红、王升启、王小宁、许景峰、李贵新、伍伟锋、Vivian WY Lee、张 伟、秦胜营、崔一民

委员（排名不分先后）：艾军、班博、鲍玉琳、陈东生、陈慧、陈世才、陈万生、冯端浩、冯刚、冯婉玉、戈伟、韩明勇、何功浩、胡军、胡永芳、贾伟平、黎月玲、李 智、李宝生、李俊生、李明春、李卫华、李雪松、梁延平、廖琳、刘勤社、刘亚利、刘逸辰、刘禹利、刘志霈、吕军、马珂、马霖、彭志海、秦晓松、沈毅、施晨阳、石　杰、宋现让、隋忠国、孙晖、孙伟、孙洲亮、唐发宽、唐少华、王飚、王传跃、王春革、王会娟、王清、王文奇、王新梦、王秀问、王哲海、王者令、谢瑞祥、徐贵丽、徐海洋、徐维平、颜真、杨婉花、尤崇革、于国平、张鉴、张克亮、张志珺、张超、丰光斌、赵庆春、钟军、周国华、朱惠莉、朱曼、董亚琳、郭其森、郭志勇、何明、侯应龙、毛拥军、石远凯、王宝成、杨莉萍、张弋、余丽梅、周国华、唐晓华、叶庆、戴鹏高、刘洁、曹舫、段金菊、傅晓辉、梁岩、欧阳冬生、齐谋甲、孙建枢、王兴宇、谢丛华、于壮、张国刚、盖中涛、侯大平、陆士娟、赵靖平、魏来、郝义彬、刘端

业务范围包括：

1.组织开展全国性药物基因组学领域的学术会议、专题研讨会、讲习班等；

2.编辑出版药物基因组学刊物、书籍和音像制品；

3.评论学术成果，提供药物基因组学学科咨询，承办政府委托的任务；

4.组织、开展全国性药物基因组学领域的国际学术交流活动；

5.传播药物基因组学与个体化治疗领域新知识，推广本领域先进技术、新仪器应用的交流和展示；

6.开展药物基因组学领域继续教育，举办为会员服务的活动；

7.对国家个体化治疗和重大新药创制的科技政策和经济建设中的重大问题发挥咨询作用。

A Brief Introduction to the Division of Pharmacogenomics of the Chinese Pharmacological Society

   Pharmacogenomics is a science that studies the influence ofgenetic variations on drug response in patients. Integrating pharmacology and genetics, pharmacogenomics appeared as a new interdiscipline by the time functional genomics developed. Division of Pharmacogenomics, Chinese Pharmacological Society (DPCPS) was initiated by academician Hong-hao Zhou, head of the Institute of Clinical Pharmacology, Central South University, and approved to establish by the eighth conference of the ninth General Council of Chinese Pharmacological Society. DPCPS mainly focuses on the study and practice of personalized drug therapy and rational drug use by carrying out work on academic research, education, technology development and clinical application. In the technology area, study is committed to the improvement of analytic technique and clinical application; in the academic area, basic and standardized researches on many specialties such as pharmaceutical analysis, molecular biology, cell biology, pharmacology and statistics are carried out, based on learning the relationship and interaction of Gene polymorphism – Pharmacokinetics - Pharmacodynamics.

   The establishment of DPCPS is an important milestone in the development of Chinese pharmacogenomics and personalized medicine, indicating that the research and application of Chinese pharmacogenomics and personalized medicine has entered a new stage of development. DPCPS is the leader of Chinese pharmacogenomics and personalized medicine, and it will steer and drive the development of Chinese pharmacogenomics, personalized medicine and translational medicine. At the same time, DPCPS builds a platform for exchange and cooperation of our researchers, health workers and business people in these areas. In the future, DPCPS will organize academic activities, and it also encourages the public organization of a variety of exchange activities in different regions. DPCPS will make efforts for turning its academic conferences into annually or biennially grand academic events. 

 The main work of DPCPS includes:

1.Organizing academic conferences, seminars, workshops, etc. in national pharmacogenomics field;

2.Editing and publishing journals, books and audio-visual products of pharmacogenomics;

3.Reviewing academic achievements, providing pharmacogenomics consultation and undertaking government tasks;

4.Organizing and carrying out international academic exchange activities in national pharmacogenomics field;

5.Propagating the new knowledge of pharmacogenomics and personalized medicine, and popularizing the exchange of advanced technology and display of new equipment in these areas;

6.Carrying out the continuing education in pharmacogenomics field and organizing activities to serve members;

7.Playing an advisory role in the key issues of science and technology policy and economic development in the area of Chinese personalized medicine and new drug discovery.